

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



B2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07F 9/09		A1	(11) International Publication Number: WO 99/35150 (43) International Publication Date: 15 July 1999 (15.07.99)
(21) International Application Number: PCT/US99/00419 (22) International Filing Date: 8 January 1999 (08.01.99)		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>With amended claims.</i>	
(30) Priority Data: 60/071,070 9 January 1998 (09.01.98) US 60/111,531 9 December 1998 (09.12.98) US			
(71) Applicant (for all designated States except US): ARIZONA BOARD OF REGENTS, a body corporate, acting on behalf of ARIZONA STATE UNIVERSITY [US/US]; Tempe, AZ 85287 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): PETTIT, George, R. [US/US]; 6232 Bret Hills Drive, Paradise Valley, AZ 85253 (US). RHODES, Monte, R. [US/US]; 8115 Copper Creek Drive, Louisville, KY 40222 (US). (74) Agent: MYBECK, Richard, R.; Suite 10, 8010 East Morgan Trail, Scottsdale, AZ 85258 (US).			
(54) Title: SYNTHESIS OF COMBRETASTATIN A-4 PRODRUGS AND TRANS-ISOMERS THEREOF			
(57) Abstract			
<p>Combretastatin A-4 has been previously selected for pre-clinical development as antineoplastic agents. However, it is essentially insoluble in water. New water soluble derivatives of combretastatin A-4 and its qualified analogs have been discovered and synthesized through a multistage process using other derivatives of combretastatin A-4 as intermediates. These water soluble derivatives are herein denominated as "Combretastatin A-4 Prodrugs".</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Synthesis of Combretastatin A-4 Prodrugs
and Trans-isomers Thereof

5 The present invention relates generally to the field of compounds which may be useful in the treatment of one or more neoplastic diseases and more particularly, this invention relates to the synthesis of water soluble prodrugs of the antineoplastic compound denominated "combretastatin A-4."

10 This research was funded in part by Outstanding Investigator Grant CA44344-05-09 awarded by the National Cancer Institute, DHHS. The United States government may have certain rights to this invention.

15 The present invention relates to new and improved methods of synthesizing prodrugs and trans-isomers of the known antineoplastic compound denominated combretastatin A-4.

20 In addition, this invention teaches the chemistry of forming phosphate salts by reaction with the phenolic hydroxy group present in combretastatin A-4 and its analogs as described in U.S. Patents 4,940,726; 5,409,953; and 5,569,786. combretastatin A-4 has poor water solubility distribution within biological systems. The elucidation and isolation of combretastatin A-4 is described in U.S. Patent No. 4,996,237 which issued to G.R. Pettit et al., on February 26, 1991, while early efforts to develop a combretastatin A-4 prodrug are described in U.S. Patent No. 5,561,122, which issued to G.R. Pettit on October 1, 1996. The general background information from each of those patents is incorporated herein by this reference thereto.

25 The potent cancer cell growth and tubulin assembly inhibitor combretastatin A-4 was originally isolated from the African tree *Combretum caffrum* (*Combretaceae*) circa 1985 and has been undergoing preclinical development. However, because of the very sparing aqueous solubility behavior of the phenol and its alkali metal salts, drug formulation attempts have given unsatisfactory results. The present invention represents a breakthrough in the

continuing effort to synthesize practical water soluble prodrugs based on combretastatin A-4 and is a significant advance over the early efforts described in U.S. Patent No. 5,561,122, *supra*.

5 In certain African Zulu traditional practices, the root bark of *Combretum caffrum* (*C. salicoylum*, *combretaceae* Family) is used as a charm for causing harm to an enemy. Combretastatin A-4, 1a, a Z-stilbene, isolated (Pettit *et al.*, 1989, Isolation and structure of the strong cell-growth and tubulin inhibitor combretastatin A-4, *Experimentia*, 45, 209) from this tree has been shown to be a potent cancer cell growth inhibitor (El-Zayat *et al.*, 1993, *In vitro* evaluation of the antineoplastic activity of combretastatin A-4, a natural product from *Combretum caffrum* (arid shrub), *Anti-Cancer Drugs*, 4, 19); cancer anti-agent (Dark *et al.*, 1997, combretastatin A-4, an agent that displays potent and selective toxicity towards tumour vasculature); and a tubulin assembly inhibitor (Lin *et al.*, 1989, Antimitotic natural products combretastatin A-4 and combretastatin 10 A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin, *Biochemistry*, 28, 6984). Combretastatin a-4 is now in clinical development.

15

20 Although combretastatin A-4 has a phenol hydroxyl group and has demonstrated considerable promise as a unique anticancer agent, its development has been inhibited by its extremely poor solubility in water. A series of water-soluble derivatives have been recently reported (Brown *et al.*, 1995, Synthesis of water-soluble sugar derivatives of combretastatin A-4, *Journal of the Chemical Society, Perkin Transactions I*, 577; Woods *et al.*, 1995, The interaction with tubulin of a series of stilbenes based on combretastatin A-4, *British Journal of Cancer*, 71, 705; and, Bedford *et al.*, 1996, Synthesis of Water-Soluble Prodrugs of the Cytotoxic Agent combretastatin A-4, *Bioorganic & Medicinal Chemistry Letters*, 6, 157) where the water-soluble phosphate sodium salt, 1h, (Pettit *et al.*, 1995, Antineoplastic agents 322, Synthesis of combretastatin A-4 prodrugs, *Anti-Cancer Drug Design*, 10, 299; and, Pettit, U.S. 25

5

Patent No. 5,561,122) proved to be the most attractive. However, the phosphorylation sequence employing *bis*(2,2,2-trichloroethyl)phosphoro-chloride, subsequent reduction (Zn, CH₃CO₂H), and isolation by ion-exchange chromatography was not well suited to producing prodrug **1h** on a large scale and as such, posed a significant economic obstacle to its ultimate commercialization.

10

15

20

25

While prodrug options are steadily increasing and include poly(ethylene glycol) esters (Greenwald *et al.*, 1996, Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and *in vivo* effectiveness, *The Journal of Medicinal Chemistry*, 39, 424); quaternary salts (Lackey *et al.*, 1996, Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin, *The Journal of Medicinal Chemistry*, 39, 713); sulfonate salts (Hejchman *et al.*, 1995, Synthesis and cytotoxicity of water-soluble ambrosin prodrug candidates, *The Journal of Medicinal Chemistry*, 38, 3407); urethans (Izawa *et al.*, 1995, Design and synthesis of an antitumor prodrug released by the reaction with sulphydryl compounds, *Bioorganic & Medicinal Chemistry Letters*, 5, 593); biodegradable polymers (Gombotz *et al.*, 1995, Biodegradable polymers for protein and peptide drug delivery, *Bioconjugate Chemistry*, 6, 332); and, a variety of other methods (Jungheim *et al.*, 1994, Design of antitumor prodrugs: substrates for antibody targeted enzymes, *Chemical Reviews*, 94, 1553), the present disclosure is focused on the previously introduced sodium phosphate derivative **1h** (which is equivalent to the sodium phosphate derivative **3d**, produced by the methods set forth herein, see below) of combretastatin A-4. From evidence at hand phosphate **1h** (as well as **3d**) is presumed to be appropriately dephosphorylated by serum phosphatases and then transported intracellularly.

Furthermore, the phosphate prodrug approach has proved useful with substances as diverse as Etoposide (Saulnier *et al.*, 1994, Synthesis of etoposide phosphate, BMY-40481: a water-soluble clinically active prodrug of etoposide,

Bioorganic & Medicinal Chemistry Letters, 4, 2567); Taxol (Mamber *et al.*, 1995, Tubulin polymerization by paclitaxel (Taxol) phosphate prodrugs after metabolic activation with alkaline phosphatase, *The Journal of Pharmacology and Experimental Therapeutics*, 374, 877; Ueda *et al.*, 1995, Novel, water-soluble phosphate derivatives of 2'-ethoxycarbonylpaclitaxel as potential prodrugs of paclitaxel; synthesis and antitumor evaluation, *Bioorganic & Medicinal Chemistry Letters*, 5, 247; and Ueda, *et al.*, 1993, Novel water soluble phosphate prodrugs of Taxol possessing *in vivo* antitumor activity, *Bioorganic & Medicinal Chemistry Letters*, 3, 1761); and tyrosine-containing peptides (Chao *et al.*, 1993, N,N-Diisopropyl-bis[2-(trimethylsilyl)ethyl]phosphoramidite, An attractive phosphorylating agent compatible with the Fmoc/t-butyl strategy for the synthesis of phosphotyrosine containing peptides, *Tetrahedron Letters*, 34, 3377). As shown herein below for prodrug 1h (also, 3d), phosphate ester salts are generally cleaved *in vivo* (Bundgaard (ed.), 1985, Design of prodrugs, pp. 1-92, Elsevier: New York) and are stable enough to usually allow formulation into solutions with practical shelf lives (Flynn *et al.*, 1970, Factors influencing solvolysis of corticosteroid-21-phosphate esters, *Journal of Pharmaceutical Sciences*, 59, 1433). To improve the synthetic scaleup practicality for the sodium phosphate ester prodrug 1h (3d) of combretastatin A-4, three new phosphate esters have been synthesized which were easily transformed into the water-soluble prodrug 3d as is herein described.

The aggressive behavior of a broad spectrum of human cancer types such as breast carcinoma is related to the facility for rapid tumor angiogenesis. Neovascularization represents a very attractive target for new tumor antiangiogenesis-type anticancer drugs. Combretastatin A-4 1a was found to show potent antiangiogenesis activity and the derived sodium phosphate prodrug 1h (3d) is a powerful *in vivo* inhibitor of tumor vascularization. Currently prodrug 1h is in clinical development. A practical synthetic procedure for providing the pure drug in quantity for clinical trials has

continued to be an important research objective. As described, the present invention is predicated upon the discovery of a considerably improved sequence utilizing *in situ* prepared dibenzyl chlorophosphite for phosphorylating phenol 1a, cleavage of the benzyl ester groups by trimethyliodosilane and treatment of the product with sodium methoxide to afford prodrug 1h (herein 3d) in good yield. However, the product was found to be accompanied by an isomeric substance that was first revealed by the appearance of some opalescence in aqueous solutions of prodrug 3d. The side product was believed to be the corresponding *trans*-stilbene 4c and was eliminated by extraction and fractional recrystallization. The purity of prodrug 3d was readily assigned by an ion-pair HPLC analysis using a phosphate buffer.


This further study was focused on confirming the structure of the persistent by-product (assumed to be 4c) by synthesis. In addition, the evaluation of combretastatin A-4 prodrugs was extended by preparing an extended series of phosphate metal and ammonium cation derivatives of the phosphoric acid precursor of prodrug 3d. Synthesis of the *trans*-stilbene phosphate 4c was also considered potentially useful for SAR purposes in view of the chemopreventative activities of certain *trans*-stilbene phenols such as resveratrol.

Combretastatin A-4 is essentially insoluble in water. This characteristic has significantly interfered with accomplishing the necessary formulations of pharmaceutical preparations of this compound for use in pre-clinical development. Hence, derivatives of the combretastatin A-4, 1a, 3' phenol group were prepared for evaluation as possible water soluble prodrugs. As noted in U.S. Patent No. 5,561,122, the sodium salt 1b, potassium salt 1c and hemisuccinic acid ester 1d derivatives of phenol 1a were essentially insoluble in water. Indeed, these substances regenerated combretastatin A-4 upon reaction with water. A series of other simple derivatives proved unsatisfactory in terms of water solubility or stability or both. The most soluble derivatives


evaluated included the ammonium **1f**, potassium **1g** and sodium **1h** phosphate salts where the latter two proved most stable and suitable. Both the sodium and other phosphate salt derivatives of combretastatin A-4 described herein were also found to exhibit the requisite biological properties necessary for a useful prodrug.

5

10



1a, R = H
b, R = Na
c, R = K
d, R = $\text{COCH}_2\text{CH}_2\text{CO}_2\text{H}$
e, R = $\text{O}=\text{P}(\text{OCH}_2\text{CCl}_3)_2$
f, R = ammonium phosphate salt
g, R = potassium phosphate salt
h, R = sodium phosphate salt, e.g.




15

20

25

Combretastatin A-4 **1a**, as the phosphate ester prodrug **1h** (and, hereinafter **3d**) is a potent antineoplastic and antiangiogenesis substance and is in clinical development. For the purpose of improving the phosphorylation synthetic sequence from combretastatin A-4, new routes were investigated. The phosphorylation step was found to be considerably improved using *in-situ* generated dibenzyl chlorophosphite. Cleavage of the benzyl esters employing a trimethylchlorosilane/sodium iodide procedure, followed by treatment with sodium methoxide, led to the water-soluble prodrug **3d** in high yield.



15


As shown more particularly above for prodrug **3d**, phosphate ester salts are generally cleaved *in vivo* (Bundgaard, *supra*). To improve the synthetic scaleup practicality for the sodium phosphate ester prodrug of combretastatin A-4, three new phosphate esters **3a**, **3b**, and **3c** have been synthesized the latter of which was easily transformed into the water-soluble prodrug **3d** as is described in more detail below.

20


25

The (E)-stilbene isomer **4c** (see below) of the natural (Z)-combretastatin A-4 prodrug **3d** was also efficiently prepared from (E)-combretastatin A-4 **1a** by an analogous reaction sequence employing phosphorylation (dibenzyl chlorophosphite), cleavage (trimethylsilyl iodide) of the benzyl ester and reaction of the resulting phosphoric acid with sodium methoxide. The sodium phosphate product **4c** was found to be an important side-product, presumably from iodine-catalyzed isomerization, when this synthetic route was used to obtain the combretastatin A-4 prodrug **3d**.

5



1a, R = OH
3d, R = $\text{OPO}_3\text{H}(\text{Na})$




4a, R = OH
b, R = OPO_3Bn_2
c, R = $\text{OPO}_3\text{H}(\text{Na})$

10

15

The phosphoric acid precursor of prodrug **3d** derived from (Z)-combretastatin A-4 **1a** was also converted to a series of metal cation and ammonium cation salts to evaluate effects on human cancer cell growth, antimicrobial activities and solubility behavior. Thus, several new combretastatin A-4 prodrug modifications **5a-s** (see below) have been prepared and found to exhibit inhibitory action against various bacteria and opportunistic fungi.

20




where X=H(Z) (monovalent)
or
X=Z (divalent)

25

5a Z = Ca^{2+}	g Z = imidazole	m Z = adenosine
b Z = Cs^{2+}	h Z = morpholine	n Z = cinchonine
c Z = Li^+	i Z = piperazine	o Z = glucosamine
d Z = Mg^{2+}	j Z = piperidine	p Z = quinine
e Z = Mn^{2+}	k Z = pyrazole	q Z = quinidine
f Z = Zn^{2+}	l Z = pyridine	r Z = tetracycline
		s Z = verapamil

5



verapamil

10

15

Accordingly, the prime object of the subject invention is to prepare prodrugs of combretastatin A-4 which are both water soluble and stable, as well as to improve the means of synthesizing such compounds.

20

These and still further objects as shall hereinafter appear are readily fulfilled by the present invention in a remarkably unexpected manner as will be readily discerned from the following detailed description of an exemplary embodiment thereof especially when read in conjunction with the structures set forth above and the accompanying drawing.

FIG. 1 comprises high performance liquid chromatography charts for a) mixture of (Z)- and (E)-combretastatin A-4 prodrugs b) combretastatin A-4 prodrug, 100% pure by HPLC.

25

The process by which combretastatin may be synthesized is well known in the art. See, Pettit et al., Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4, *Experimentia*, 209 (1989), *supra*. Combretastatin A-4, synthesized by that method disclosed in U.S. Patent No. 4,996,237 ("the '237 patent"), was used throughout this process.

Combretastatin A-4 (**1a**) was synthesized as previously described by Pettit *et al*, in 1995. Diisopropylethylamine (98%), lithium hydroxide monohydrate, cesium hydroxide, zinc acetate dihydrate, quinine monohydrate, piperidine, pyrazole, and sodium methoxide (95%), dibenzyl phosphite, 4-dimethylaminopyridine (DMAP), 1*H*-Tetrazole (98%), 85% 3-chloroperoxybenzoic acid (*m*-CPBA), chlorotrimethylsilane (98%), trifluoroacetic acid (99%), triethylamine, and sodium methoxide (95%) were obtained from Sigma-Aldrich Chemical Company. The *tert*-butanol was obtained from Acros Organics. Calcium acetate, magnesium acetate tetrahydrate, manganese acetate and other reaction and isolation reagents were obtained from the Baker Chemical Company. Tetrahydrofuran was distilled from sodium/benzophenone. Imidazole was recrystallized from *n*-hexane, and piperazine was recrystallized from ethanol and dried *in vacuo*. The morpholine was dried with KOH and then fractionally distilled; pyridine was dried over CaH₂ and fractionally distilled, then stored over KOH. Adenosine was obtained from Nutritional Biochemicals Corporation; cinchonine, from Mateson, Cole & Bell and was recrystallized from ethanol prior to use; D-glucosamine was from Nutritional Biochemicals Corporation; quinidine, was from J. T. Baker; tetracycline, from Mateson, Cole & Bell; and verapamil, from the Alexis Corporation. "Ether", refers to diethyl ether. All solvents were redistilled prior to use. The 1.0 M solutions of the metal salts were in distilled water, and the 1.0 M solutions of the amines were in dry methanol. The di-*tert*-butyloxy(N,N-diethylamido)phosphine was prepared as previously described by Johns *et al* (1988, Di-*tert*-butyl N,N-Diethylphosphoramidite, A New Phosphitylating Agent for the Efficient Phosphorylation of Alcohols, *Synthesis*, pp. 142-144).

Reactions were monitored by thin-layer chromatography using ANALTECH silica gel GHLF Uniplates visualized under long-wave and short-wave UV irradiation. Solvent extracts of aqueous solutions were dried over anhydrous sodium sulfate. Where appropriate, the crude products were

separated by flash column chromatography (230-400 mesh ASTM) from E. Merck.

Melting points were measured with an ELECTROTHERMAL digital melting point apparatus, model IA9200, and are uncorrected. The IR spectra were obtained using a NICOLET FTIR Model MX-1 instrument. EIMS data was recorded with a MAT 312 mass spectrometer, and high-resolution FAB spectra were obtained with a KRATOS MS-50 mass spectrometer (Midwest Center for Mass Spectrometry, University of Nebraska, Lincoln, NE). All ¹H- and ¹³C-NMR spectra were obtained using a VARIAN GEMINI 300 MHz instrument with CDCl₃ (TMS internal reference) as solvent unless otherwise noted. The ³¹P-NMR spectra were obtained in CDCl₃ with 85% H₃PO₄ as an external standard employing a UNITY 500 MHz instrument. Elemental analyses were determined by Galbraith Laboratories, Inc., Knoxville, TN.

HPLC Separations and Analysis

HPLC analyses were performed on a HEWLETT-PACKARD HP 1050 Series 3D CHEMSTATION, Rev. A.03.01, liquid chromatograph. All solvents used were HPLC grade and filtered before use. HPLC separation and analysis procedures were based on aqueous buffered ion-pair reverse-phase gradient elution at 33°C. Flow rate: 1.2 ml/min. Column: MERK LICHROSPHERE 100 RP 18 (5 μ m), 250 x 4.0 mm (LICHROCART 250-4). Eluents: Eluent A. 5mM tetrabutylammonium hydrogen sulfate, 5 mM H₃PO₄, 5 mM KH₂PO₄. Eluent B. 75% CH₃CN. Gradient: a) Hold 4 minutes at 65% A, 35% B, b) 8 minutes linear gradient, 65% A to 10% A, c) Hold 3 minutes. Detector: 310 nm UV.

di-tert-Butyloxy(N,N-diisopropylamide)phosphine (2a)

A solution of *tert*-butanol (3.7 g, 4.7 ml, 50 mmol, 2.0 equiv) and triethylamine (5.6 g, 7.7 ml, 55 mmol, 2.2 equiv) in dry ether (20 ml) was added to dichloro-N,N-diisopropylphosphine (5.0 g, 25 mmol) in dry ether (5 ml) while maintaining the solution temperature below 0°C. Upon completion

of addition (about 15 minutes), the solution was allowed to warm to room temperature and stirred for a further 3 hours. A solution of 5% aqueous sodium bicarbonate (10 ml) was added, the aqueous phase was removed, and the ethereal solution was washed with 5% aq. sodium bicarbonate (2 x 10 ml), 5 saturated aq. NaCl (25 ml), dried, filtered, and solvent removed to give a clear residual oil. Purification by vacuum distillation gave the product as a clear oil (4.3 g, 63%). b.p. 56-57°C/0.05 mm Hg; ¹H-NMR (300 MHz) δ 1.17 (d, *J*=6.0 Hz, CH(CH₃)₂), 1.35 (s, 18H, 2 x (CH₃)₃C), 3.53-3.68 (m, 2 x (CH₃)₂CH); ¹³C-NMR (125 MHz) δ 24.21 (d, *J*_{PC}=7.73 Hz), 31.06 (d, *J*_{PC}=9.75 Hz), 43.09 (d, *J*_{PC}=13.88 Hz), 74.50 (d, *J*_{PC}=9.75 Hz); ³¹P-NMR (202 MHz) δ 130.0 (s).

10 *di-tert-Butyloxy(N,N-diethylamido)phosphine (2b)*

15 Phosphine **2b** was as previously described (Johns *et al*, 1988, *supra*): b.p. 49-51°C/0.005 mm Hg (55% yield); ¹H-NMR (300 MHz) δ 1.06 (t, 6H, *J*_{HH}=7.8 Hz), 1.33 (s, 18H, C(CH₃)₃), 3.03 (dq, 4H, *J*_{HH}=7.8 Hz, *J*_{PH}=9.0 Hz, PCH₂CH₃); ¹³C-NMR (75 MHz) δ 14.84 (d, *J*_{PC}=3.9 Hz), 30.88 (d, *J*_{PC}=9.75 Hz), 37.45 (d, *J*_{PC}=21.3 Hz), 74.40 (d, *J*_{PC}=11.63 Hz).

20 *Bis-[2-(trimethylsilyl)ethoxy]-N,N-diisopropylamidophosphine (2c)*

25 A solution of 2-(trimethylsilyl)ethanol (1.2 g, 9.9 mmol, 2 equiv) and triethylamine (1.5 ml, 10.9 mmol, 2.2 equiv) in dry ether (10 ml) was added to dichloro-N,N-diisopropylamidophosphine (1.0 g, 4.9 mmol) in dry ether (10 ml) and the temperature was maintained below 0°C. Upon completion of addition (ca 30 min), the mixture was allowed to warm to room temperature and stirring continued for 3 hours. After adding a solution of 5% aq. NaHCO₃ (10 ml) the aqueous phase was washed with 5% aq. NaHCO₃ (2 x 10 ml), saturated aq NaCl (10 ml), dried and filtered. Removal of solvent *in vacuo* afforded a clear oil (2.2 g, 78%). Purification by vacuum distillation gave the product as a clear oil. b.p. 62-64°C/0.005 mm; IR (neat) ν_{max} 2960 (s), 2897 (m), 1462 (w), 1396 (m), 1363 (m), 1249 (s), 1186 (s), 1126 (m) 1045 (s), 972 (s), 837 (s), 744 (s), 694 (s), 663 (w) cm⁻¹; ¹H-NMR (300 MHz) δ 0.00 (s, 18H), 1.02 (m, 4H) 1.16

(d, $J=6.6$ Hz, 12H), 3.52-3.77 (m, 6H); ^{13}C -NMR (75 MHz) δ -1.49, 20.00, 24.41, 24.51, 42.47, 42.63, 60.43, 60.67; ^{31}P -NMR (202 MHz) δ 143.50.

3-O-Bis(benzyl)phosphorylcombretastatin A-4 (3a)

A flame-dried, 3-neck flask containing a teflon stirbar was fitted with a 5 septa, thermometer, and argon inlet. The phenol (1a, 20.0 g, 63.2 mmol) was dissolved in acetonitrile (200 ml) with stirring and then cooled to -25°C. Carbon tetrachloride (30.5 ml, 316 mmol, 5 equiv) was added and the solution stirred for 5 minutes. Diisopropylethylamine (23.13 ml, 133 mmol, 2.1 equiv) was added *via* syringe, followed by DMAP (772 mg, 6.32 mmol, 0.1 equiv). 10 One minute later dropwise (slow) addition of dibenzyl phosphite (20.33 ml, 92 mmol, 1.45 equiv) was begun at such a rate that the reaction temperature was kept below -10°C. When the reaction was complete (1 hr by TLC analysis) 0.5 M aqueous KH_2PO_4 was added (50 ml) and the solution allowed to warm to room temperature. After extraction with ethyl acetate (3 x 100 ml), the 15 combined solvent extract was washed with water (100 ml), saturated NaCl (100 ml) and dried. Filtration and removal of solvent under reduced pressure gave a faint yellow oil. The oily residue was chromatographed on a column of silica gel (hexane-ethyl acetate, 3:2) to give a clear oil which crystallized from ethyl acetate-hexane to give pure, colorless needles (36.0 g; 98%): m.p. 73°C; R_f 0.26 20 (hexane-ethyl acetate, 3:2); EIMS m/z 576 (100, M^+), 561 (8), 485 (2), 394 (2), 378 (3), 363 (3), 252 (5), 181 (3); IR (neat) ν_{max} 3005, 2939, 2837, 1579, 1512, 1454, 1425, 1280, 1240, 1122, 1010, 891, 740, 698 cm^{-1} ; ^1H -NMR (300 25 MHz) δ 3.67 (s, 6H, 2 x OCH_3), 3.77 (s, 3H, OCH_3), 3.80 (s, 3H, OCH_3), 5.12 (s, 2H, $\text{CH}_2\text{-Ar}$), 5.14 (s, 2H, $\text{CH}_2\text{-Ar}$), 6.40 (d, $J=12.0$ Hz, 1H), 6.45 (d, $J=12.0$ Hz, 1H), 6.48 (s, 2H), 6.78 (d, $J=9.0$ Hz, 1H), 7.06 (dd, $J=9.0, 1.8$ Hz, 1H), 7.15 (d, $J=1.8$ Hz, 1H), 7.31 (s, 1OH, Ar-H); ^{13}C -NMR (75 MHz) δ 152.97, 139.32, 139.22, 135.67, 132.46, 130.19, 129.67, 128.53, 127.88, 126.56, 122.21, 112.27, 105.93, 69.79, 69.72, 60.86, 60.40, 55.92, 21.05, 14.22; ^{31}P -NMR

(202 MHz) δ -5.29; Anal. Calcd. for $C_{32}H_{33}O_8P$: C, 66.67; H, 5.77. Found: C, 66.96; H, 6.05.

3-O-Bis(tert-butyl)phosphorylcombreastatin A-4 (3b)

Method A: 1*H*-Tetrazole (3.73 g, 53 mmol, 3.67 equiv) was added in one portion to a stirred solution of combretastatin A-4 (1a, 5.00 g, 16 mmol, 1.0 equiv) and di-tert-butyloxy-N,N-diethylamidophosphine (5.19 g, 21 mmol, 1.3 equiv) in dry tetrahydrofuran (15 ml). The solution was stirred under argon for 20 minutes at room temperature and cooled to -70°C (CO_2 /acetone). Next a solution of 85% *m*-CPBA (3.22 g, 19.0 mmol) in dry dichloromethane (10 ml) was added (rapidly) such that the reaction mixture temperature was kept below -30°C. After stirring for 5 min at room temperature, 10% aqueous sodium bicarbonate (15 ml) was added. The solution was stirred for another 10 minutes and extracted with ether (70 ml). The ethereal phase was washed with 10% aq. sodium bicarbonate (2 x 20 ml), 1N NaOH (6 x 40 ml), dried and filtered. Evaporation of solvent under reduced pressure gave a yellow oil which was purified by flash column chromatography (silica gel; 3:2 hexane-ethyl acetate) to give the title compound as a clear oil (1.15 g; 75%): R_f 0.25 (hexane-ethyl acetate, 3:2); EIMS m/z 508 (M^+ , 22), 452 (5), 437 (7), 396 (100), 381 (17), 364 (4), 349 (3), 316 (5); IR (neat) ν_{max} 3462, 2980, 2937, 2837, 2243, 1579, 1512, 1462, 1425, 1371, 1327, 1276, 1174, 1128, 999, 920, 868, 731, 646 cm^{-1} ; 1H -NMR (300 MHz) δ 1.47 (s, 18H, 2 x $C(CH_3)_3$), 3.69 (s, 6H, 2 x OCH_3), 3.82 (s, 3H, OCH_3), 3.83 (s, 3H, OCH_3), 6.42 (d, J =12 Hz, 1H), 6.47 (d, J =12 Hz, 1H), 6.51 (s, 2H, 2,6-H), 6.79 (d, J =8.5 Hz, 1H), 7.03 (dd, J =8.5, 1.8 Hz, 1H), 7.31 (d, J =1.8 Hz, 1H); ^{13}C -NMR (75 MHz) δ 152.94, 132.62, 129.85, 129.25, 129.02, 125.63, 121.80, 112.14, 105.93, 99.28, 83.49, 60.89, 55.92, 29.80, 29.72; ^{31}P -NMR (202 MHz, $CDCl_3$ /85% H_3PO_4) δ -14.47; Anal. calcd. for $C_{26}H_{37}O_8P$: C, 61.40%; H, 7.33%. Found: C, 60.92; H, 7.67.

Method B: The same procedure as in Method A above was followed except di-tert-butyloxy-N,N-diisopropylamidophosphine was used as the phosphorylating agent. Yield: 78%.

3'-O-Bis(trimethylsilylethoxy)phosphorylcombreastatin A-4 (3c)

5 The same procedure as in Method A above was used, with *bis*-[2-(trimethylsilyl)ethoxy-N,N-diisopropylamidophosphine (2c), giving the product as a colorless oil (8.67g, 91%): R_f 0.26(hexane-ethyl acetate, 3:1); EIMS m/z 596 (M⁺, 90), 568 (20), 540 (21), 525 (38), 496 (10), 468 (40), 453 (13), 396 (22), 283 (10), 252 (11), 211 (13), 147 (15), 73 (100); IR (neat) ν_{max} 2999, 2955, 2901, 2837, 1579, 1512, 1464, 1525, 1276, 1249, 1217, 1180, 1128, 991, 856, 767, 696 cm⁻¹; ¹H-NMR (500 MHz) δ 0.00 (s, 18 H), 1.04 (m, 4H, -CH₂Si-), 3.63 (s, 6H, 2 x OCH₃), 3.77 (s, 6H, 2 x OCH₃), 4.17 (m, 4H, -OCH₂CH₂-), 6.09 (s, 2H), 6.42 (d, J=12.5 Hz, 1H), 6.47 (d, J=12.5 Hz, 1H), 6.77 (d, J=8.5 Hz, 1H), 7.03 (dd, J=8.5, 1.0 Hz, 1H), 7.21 (d, J=1.0 Hz, 1h); ¹³C-NMR (75 MHz) δ 152.77, 149.69, 139.54, 137.05, 132.24, 129.94, 129.37, 128.41, 126.05, 121.78, 112.08, 105.76, 66.72, 64.00, 60.59, 55.70, 19.51, 19.20, -1.72; ³¹P-NMR (202 MHz) δ -5.54.

10

15

Sodium (Z) -combreastatin A-4 3'-O-phosphate (3d)

20 *Procedure A:* To a solution of the benzyl ester (3c, 20.5 g, 35.6 mmol) and sodium iodide (10.7 g, 71 mmol, 2 equiv) in dry acetonitrile (100 ml, in a flame-dried flask under argon) was slowly added chlorotrimethylsilane (9.02 ml, 71 mmol, 2 equiv) with vigorous stirring. The reaction mixture was stirred for 20 minutes at which point TLC analysis (hexane-ethyl acetate, 3:2) showed no starting material. Water (just enough to dissolve the salts) was added and the straw color removed by the addition of 10% aq.sodium thiosulfate (2 ml). The organic phase was separated and the aqueous phase extracted with ethyl acetate (4 x 50 ml). The combined extract was concentrated *in vacuo* to give a pale yellow foam. The foam was dissolved in dry methanol (100 ml) and sodium methoxide (95%, 4.1 g, 71 mmol, 2 equiv) was added in one portion and the

25

solution stirred for 9 hours. The methanol was removed *in vacuo* and the solid recrystallized from water-acetone and methanol-acetone to give colorless crystals (14 g, 90%): m.p. 190-195°C (decomp); R_f 0.64 (n-butanol-methanol-water-ammonia, 4:3:2:1); UV λ_{max} (log ϵ) in CH₃OH, 200 (4.54), 278 (4.25) nm (4.54), 196 (4.48) nm; IR (KBr) ν_{max} 2941 m, 2839s, 2361m (broad), 1581s, 1514s, 1431m, 1240m, 1124s, 983m, cm⁻¹; ¹H-NMR (500 MHz, D₂O) δ 3.50 (s, 6H, 3,5-OCH₃), 3.57 (s, 3H, 4'-OCH₃), 3.68 (s, 3H, 4-OCH₃), 6.26 (d, 1H, J =12.5 Hz, H-1a'), 6.42 (s, 2H, H-2,6), 6.44 (d, 1H, J =12.5 Hz, H-1a), 6.63 (d, 1H, J =8.5 Hz, H-5'), 6.71 (dd, 1H, J =2, 8.5 Hz, H-6'), 7.19 (d, 1H, J =2 Hz, H-2'); ¹³C-NMR (125 MHz, D₂O) δ 153.17, 150.50, 143.40, 136.90, 134.65, 131.28, 130.97, 129.93, 124.69, 122.64, 113.58, 107.54, 61.97, 57.10, 56.90; HRFAB m/z 441.06942 [M + Na]⁺, 419 [M + H], 396 [M-Na + H]⁺. calc. 441.06912 for C₁₈H₂₀O₈PNa₂, anal. Na, 5.04%, H₂O 6.26% calc. for C₁₈H₂₀O₈PNa·1/2 H₂O hydrate, Na 5.16%, H₂O 6.07%.

Sodium phosphate **3d** prepared by Procedure A was identical (TLC and spectra) with an earlier specimen (**1h**, Pettit *et al.*, 1995, *supra*; and U.S. Patent No. 5,561,122) obtained by the initial 3'-O-bis(2,2,2-trichloroethyl)phosphoryl route and exhibited solubility in distilled water of >20 mg/ml at 25°C.

Procedure B: A mixture of the di-*tert*-butylphosphoryl ester **3b** (7.25 g) and trifluoroacetic acid (25 ml) in dry dichloromethane (25 ml) was stirred at ambient temperature for 45 minutes (cleavage complete by TLC analysis hexane-acetone, 3:1). Water (10 ml) was added and solvent evaporated. Residual TFA was removed azeotropically with toluene (3 x 20 ml), and the resulting oily residue was dried under vacuum (0.005 mm/ Hg) for 1 hour. The oil was dissolved in dry methanol (2 ml) and sodium methoxide (1.60 g, 28 mmol, 2.0 equiv) was added. The solution was stirred under argon for 14 hours, solvent was removed *in vacuo* and the remaining solid dried. The residue was dissolved in water (10 ml) and the solution filtered through a fine porosity sintered glass funnel. Concentration of the filtrate gave a white solid which

recrystallized from water-acetone to give a colorless powder (5.8 g, 92%) identical with the sample of prodrug **3d** prepared by Procedure A.

Procedure C: Tetrabutylammonium fluoride (8.38 ml, 1.0 M in THF; 8.38 mmol) was slowly added employing a syringe to a stirred (under nitrogen) solution of di-silyl ethoxyphosphoryl ester **3c** (5.0 g, 8.38 mmol) in 15 ml of anhydrous tetrahydrofuran. After 30 minutes, TLC analysis (hexane-ethyl acetate, 3:2) indicated the reaction was complete. Ice (5 g) was added, followed by ether (50 ml). The organic solvent was separated, washed with water (3 x 50 ml), dried, filtered and solvent removed *in vacuo* to yield a straw colored gum. The product was dissolved in methanol (5 ml) and sodium methoxide (0.90 g, 16.8 mmol, 2 equiv) was added. The solution was stirred under argon for 12 hours, solvent was removed under reduced pressure and the residual solid was recrystallized from water-acetone to give a colorless powder (**3d**, 3.60, 98%) identical with the product from Procedure A.

After completing the first synthesis of sodium combretastatin A-4, 3'-O-phosphate **3d** a number of other phosphorylation approaches were explored toward the objective of establishing a procedure more readily adapted to large scale synthesis. Selection of an appropriate method for phosphorylation of combretastatin A-4 **1a** was also limited by available methods for removal of the eventual phosphate protecting groups. An alternative dibenzylphosphite-carbon tetrachloride procedure proved very practical for obtaining phosphate ester **3a** in high yield (95%). Catalytic hydrogenolysis of the benzyl oxygen bonds under varied conditions gave a concomitant reduction of the olefin bridge. Other benzyl oxygen cleavage methods investigated included the use of triphenylcarbonium tetrafluoroborate, arylthiotrimethylsilane-zinc iodide, acidic alumina in a microwave and the Lewis acid SnCl_4 (Mukai *et al.*, 1996, Studies on the total synthesis of antitumor styryllactones: stereoselective total syntheses of (+)-goniofufurone, (+)-goniobutenolide A, and (-)-goniobutenolide B, *Tetrahedron*, 52, 6547). While all cleaved the benzyl group, they appeared (by

5

TLC) to cause varying levels of *cis*→*trans* isomerism. Finally, it was determined that trimethylsilyl iodine, neat or generated *in-situ*, provided the best route to obtain the corresponding phosphoric acid. Treatment of the latter with sodium methoxide gave, following recrystallization, a high overall yield of phosphate salt **3d**.

10

15

20

25

The second series of phosphorylating agents studied were the various alkylamidophosphines which have been shown to readily phosphorylate alcohols and phenols in high yield. Di-*tert*-butyloxy(N,N-diisopropylamido)phosphine **2a**, was prepared in good yield from dichloro(N,N-diisopropylamido)phosphine and *tert*-butanol. Phosphines **2b** and **2c** were prepared in a similar manner by reacting dichloro(N,N-diethylamido)phosphine and dichloro(N,N-diisopropylamido)phosphine with *tert*-butanol and 2-(trimethylsilyl)ethanol, respectively. In the presence of the catalyst, 1*H*-tetrazole, these reactive amides nicely phosphorylated phenol **1a** to give the corresponding phosphate esters **3b** and **3c** in greater than 90% yields. Cleavage of the ester protecting groups was easily affected with either trifluoroacetic acid for the *tert*-butyl ester or tetrabutylammonium fluoride for the *bis*(2-trimethylsilyl)ethyl ester. After isolation, the phosphoric acid derivative was treated with sodium methoxide in methanol to afford sodium phosphate **3d** in high yield.

The three new phosphorylation routes to prodrug **3d**, described herein, were readily employed to obtain 10 g or greater amounts without any decrease in yields or purity. The resulting phosphate prodrug **3d** samples proved to be identical with our original specimen and therefore the clinical supply requirements for combretastatin A-4 prodrug **3d** can now be met.

Comparison of the synthetic *trans*-stilbene phosphate **4c** (see below) with the impurity accompanying the scaleup synthesis of combretastatin A-4 prodrug **3d** confirmed the structural assignment. The ion-pair HPLC analysis noted above proved to be quite useful for detecting small quantities of this impurity. Apparently the *trans*-stilbene **4c** arose in inconsistent amounts by an

electrophilic bimolecular addition of iodine to form an iodonium ion and subsequent anti-addition product (Hassner *et al.*, 1970, Stereochemistry of halogen azide additions to olefins, The stability of three-membered iodonium vs bromonium ions, *Journal of the American Chemical Society*, 92, 4879; Robertson *et al.*, 1950, The kinetics of halogen addition to unsaturated compounds, Part XVIII, Iodine addition, *Journal of the Chemical Society*, 2191; Zanger *et al.*, 1975, A nuclear magnetic resonance investigation of the iodination of 1,2-disubstituted ethylenes, Evidence for a *trans* addition - *cis* elimination, *Journal of Organic Chemistry*, 40, 248; Ayres *et al.*, 1971, Reaction of iodine with olefins, Kinetics and mechanism of iodine addition to pentene isomers, *Journal of the American Chemical Society*, 93, 1389; Skell *et al.*, 1964, Stereospecific *trans* photoaddition of elementary iodine to aliphatic olefins, Bridged iodoalkyl radicals, *Journal of the American Chemical Society*, 86, 2956). Fortunately, isomeric stilbenes **3d** and **4c** have distinctive HPLC retention times in the phosphate buffer employed. The combretastatin A-4 prodrug **3d** eluted at 9.28 minutes with UV λ_{max} 290 nm and the *trans*-isomer at 9.40 minutes with UV λ_{max} 325 nm (see Fig 1a-1d). Because the *trans*-isomer phosphate salt **4c** proved to be sparingly soluble in water, it was simply removed from the *cis*-isomer phosphate salt **3d** by redissolving the combretastatin A-4 prodrug **3d** in a minimal amount of water and extracting with ethyl acetate. The (E)-stilbene **4c**, owing to its low solubility in water, partitioned selectively into the ethyl acetate. The water phase containing the (Z)-stilbene was concentrated and the residue recrystallized from water-acetone and methanol-acetone to give the 99+% pure (by HPLC) sodium combretastatin A-4 phosphate **3d** in >80% yields.

Since combretastatin A-4 binds tubulin very strongly in the colchicine binding site (Lin *et al.*, 1988, Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin, a structure-activity study, *Molecular Pharmacology*, 34, 200), with inhibition to 97% reported, it became important to replace the sodium cations in prodrug **3d** with different

cations, both divalent and monovalent, in order to examine their effects on activity and solubility. Using this same approach, the sodium ions were replaced with metal cations and a variety of ammonium cations in order to examine their possible effects on the cancer cell line and antimicrobial activities and solubility. Some of these ammonium cations were explored for the purpose of possibly obtaining a stable, water-soluble drug with the ability to reverse multi-drug resistance through interference with the p-glycoprotein mechanism. Watanabe *et al.*, 1997, *J. Nat. Cancer Inst.*, 89(7), pp. 512-518; Adams *et al.*, 1995 *Investigational New Drugs* 13:13-21; Sato *et al.*, 1995, *Cancer Chemother. Pharmacol.*, 35:271-277; Genne *et al.*, 1995, *Anti-cancer Drug Design*, 10, 103-118. Thus, prodrugs **5a-s** were synthesized and evaluated.

Once the very practical synthesis of high purity prodrug **3d** was in hand, a variety of cation derivatives of the parent phosphate were synthesized and evaluated. By treating the prodrug **3d** phosphoric acid precursor with a 1.0 M solution of the respective metal hydroxide or acetate, the corresponding salts were formed. An analogous procedure was followed for the ammonium salts, using a 1.0 M solution of the amine in methanol. For the alkaloid salts, two equivalents of the base (presuming 100% formation of the phosphoric intermediate) in a suitable solvent were added to the acid solution and allowed to react for 6-8 hours. Precipitation or recrystallization gave the products.

3-O-Bis(benzyl)phosphoryl-3,4,4,5-tetramethoxy-(E)-stilbene (4b)

(E)-combretastatin A-4 (**4a**, 2.2 g, 7 mmol) was dissolved in acetonitrile (20 ml) in a flask equipped with a septa, thermometer and argon inlet. After cooling to -25°C, carbon tetrachloride (3.38 ml, 35 mmol, 5 equiv) was added and the solution stirred for 5 minutes. With a syringe, diisopropylethylamine (2.56 ml, 14.7 mmol, 2.1 equiv) was added followed by DMAP (86 mg, 0.7 mmol, 0.1 equiv). Slow (dropwise) addition of dibenzyl phosphite (2.24 ml, 10.2 mmol, 1.45 equiv) was begun one minute later at such a rate that the reaction temperature remained below -20°C. The reaction was complete in 1

5

10

15

20

25

hour (by TLC analysis), 0.5 M KH_2PO_4 was added (5 ml), the solution allowed to warm to room temperature and extracted with ethyl acetate (3 x 20 ml). The combined solvent extract was washed with water (25 ml), saturated NaCl (25 ml) and dried. Filtration and removal of solvent gave an oil that was chromatographed on a column of silica gel (hexane-ethyl acetate, 3:2) to give phosphate ester **4b** as a clear gum (3.96 g, 98%): R_f 0.15 (hexane-ethyl acetate, 3:2); EIMS m/z (% intensity) 576 (M^+ , 100), 561 (12), 486 (3), 406 (6), 394 (2), 378 (6), 364 (7), 316 (17), 301 (10), 252 (8), 241 (5), 181 (5); IR (neat) ν_{max} 3005, 2939, 2839, 1734, 1581, 1512, 1456, 1425, 1346, 1278, 1126, 1008, 900, 823, 740, 698 cm^{-1} ; $^1\text{H-NMR}$ (300 MHz) δ 3.80 (s, 3H, OCH_3), 3.87 (s, 3H, OCH_3), 3.91 (s, 6H, 2 x OCH_3), 5.18 (s, 2H, $\text{CH}_2\text{-Ar}$), 5.21 (s, 2H, $\text{CH}_2\text{-Ar}$), 6.69 (s, 2H), 6.81 (d, $J=16.5$ Hz, 1H), 6.88 (d, $J=16.5$ Hz, 1H), 6.89 (d, $J=9.3$ Hz, 1H), 7.24 (m, 1H), 7.34 (s, 10H, Ar-H), 7.42 (t, $J=3.3$ Hz, 1H); $^{13}\text{C-NMR}$ (75 MHz) δ 153.41, 150.22, 139.87, 135.78, 133.06, 130.57, 128.53, 127.93, 127.65, 126.82, 124.28, 119.00, 112.71, 103.47, 69.95, 60.97, 56.13; $^{31}\text{P-NMR}$ (202 MHz) δ -5.52; Anal. calcd. for $\text{C}_{32}\text{H}_{33}\text{O}_8\text{P}$: C, 66.67; H, 5.77. Found: C, 66.71; H, 5.93.

Sodium (E)-comptastatin A-4 3'-O-phosphate (4c)

Chlorotrimethylsilane (0.88 ml, 6.9 mmol, 2 equiv) was slowly added (with vigorous stirring) to a solution of the benzyl ester (**4b**, 2.0 g, 3.5 mmol) and sodium iodide (1.04 g, 6.9 mmol, 2 equiv) in dry acetonitrile (10 ml, in a flame-dried flask under argon). After stirring for 20 minutes, TLC analysis (hexane-ethyl acetate, 3:2) showed no starting material. Enough water was added to dissolve the salts and the straw color removed by the addition of 10% aq. sodium thiosulfate (5 drops). The solvent was separated and the aqueous phase extracted with ethyl acetate (4 x 10 ml). The combined extract was concentrated *in vacuo* and the resulting foam was dissolved in dry methanol (100 ml). Sodium methoxide (95%, 375 mg, 6.9 mmol, 2 equiv) was added in one portion and the solution stirred for 6 hours. The methanol was removed under

reduced pressure and the solid recrystallized from methanol-acetone to give an off-white powder (1.43 g, 93%): m.p. 157-158°C; R_f 0.45 (n-butanol-methanol-water-ammonia, 4:3:2:1); UV λ_{max} 325 nm; IR (KBr) 2939, 2839, 1583, 1512, 1464, 1423, 1340, 1253, 1126, 991, 923, 856, 819, 773, 717, 644 cm⁻¹; ¹H-NMR (500 MHz, CD₃OD) δ 3.73 (s, 3H, OCH₃), 3.84 (s, 3H, OCH₃), 3.87 (s, 6H, 5 2 x OCH₃), 6.82 (s, 2H), 6.92 (d, J =8.5 Hz, 1H), 7.00 (d, J =16 Hz, 1H), 7.03 (d, J =16 Hz, 1H), 7.10 (dd, J =8.5 Hz, 2 Hz, 1H), 7.14 (d, J =2 Hz, 1H); ¹³C-NMR (75 MHz, CD₃OD) δ 153.12, 134.07, 130.47, 127.62, 126.35, 121.20, 117.66, 112.01, 103.16, 73.70, 59.69, 55.12; ³¹P-NMR (202 MHz, CD₃OD) δ -10 1.4; HRFABMS m/z 441.0698 [M + Na]⁺, (calcd for C₁₈H₂₀O₈Na₂P, 441.0691).

General Procedure for Synthesis of Combretastatin A-4 Prodrugs

Method A (Prodrugs 5a-f)

Cesium combretastatin A-4 3'-O-phosphate (5b)

To a stirred solution of dibenzyl combretastatin A-4 3'-O-phosphate (4b, 15 0.50 g; 0.87 mmol) and sodium iodide (0.26 g, 1.74 mmol, 2 equiv) in dry acetonitrile (4 ml) in a flame-dried flask under argon was slowly added *via* syringe chlorotrimethylsilane (0.22 ml, 1.74 mmol, 2 equiv). The mixture was stirred at room temperature until the reaction was complete by TLC (\approx 20 20 min). Enough water was added to dissolve the salts and the straw color was removed by the addition of 10% sodium thiosulfate (4 drops). The aqueous phase was extracted with ethyl acetate (4 x 5 ml) and the combined extract was concentrated under reduced pressure to a light straw foam. After adding distilled water (2 ml) and 1.0 M aqueous CsOH (1.74 ml, 1.74 mmol) dropwise, the solution became cloudy. The mixture was stirred for 6 hours under argon, 25 whereupon the precipitate was collected and recrystallized from water-acetone to afford a colorless powder (0.51 g) m.p. 167-168°C; ¹H-NMR (300 MHz, D₂O) δ 3.70 (s, 6H, 2 x OCH₃), 3.76 (s, 3H, OCH₃), 3.83 (s, 3H, OCH₃), 6.53 (d, J =12.3 Hz, 1H), 6.65 (d, J =12.3 Hz, 1H), 6.68 (s, 2H), 6.86 (d, J =8.4 Hz, 1H), 6.90 (dd, J =8.4, 1.8 Hz, 1H), 7.32 (d, J =1.8 Hz, 1H).

Calcium combretastatin A-4 3'-O-phosphate (5a)

Reprecipitated from water-acetone to give a colorless powder (147 mg):
m.p. 293-295°C (dec); $^1\text{H-NMR}$ (300 MHz, D_2O) δ 3.69 (s, 6H, 2 x OCH_3),
3.74 (s, 3H, OCH_3), 3.81 (s, 3H, OCH_3), 6.54 (d, $J=12.4$ Hz, 1H), 6.67 (d,
5 $J=12.4$ Hz, 1H), 6.69 (s, 2H), 6.85 (d, $J=8.1$ Hz, 1H), 6.91 (dd, $J=8.1, 1.8$
Hz, 1H), 7.21 (d, $J=1.8$ Hz, 1H).

Lithium combretastatin A-4 3'-O-phosphate (5c)

Recrystallized from water-acetone to give a colorless powder (151 mg):
m.p. 241-242°C; $^1\text{H-NMR}$ (300 MHz, D_2O) δ 3.56 (s, 6H, 2 x OCH_3), 3.62 (s,
10 3H, OCH_3), 3.70 (s, 3H, OCH_3), 6.38 (d, $J=12$ Hz, 1H), 6.52 (s, 2H), 6.53 (d,
 $J=12$ Hz, 1H), 6.73 (dd, $J=8.4, 1.4$ Hz, 1H), 7.24 (bd, $J=1.4$ Hz, 1H).

Magnesium combretastatin A-4 3'-O-phosphate (5d)

Recrystallization from methanol-acetone afforded a creme-colored solid
(121 mg): m.p. 270°C (dec); $^1\text{H-NMR}$ (300 MHz, D_2O) δ 3.54 (s, 6H, 2 x
15 OCH_3), 3.62 (s, 3H, OCH_3), 3.72 (s, 3H, OCH_3), 6.34 (d, $J=12.3$ Hz, 1H),
6.48 (s, 2H), 6.50 (d, $J=12.3$ Hz, 1H), 6.75 (m, 2H), 7.20 (s, 1H).

Manganese combretastatin A-4 3'-O-phosphate (5e)

Recrystallization from water-acetone gave a creme-colored solid (143
mg): m.p. 241-242°C (dec); $^1\text{H-NMR}$ (300 MHz, D_2O) δ 3.66 (s, 6H, 2 x
20 OCH_3), 3.73 (s, 3H, OCH_3), 3.82 (s, 3H, OCH_3), 6.46 (d, $J=12.3$ Hz, 1H),
6.58 (s, 2H), 6.59 (d, $J=12.3$ Hz, 1H), 6.87 (d, $J=8.7$ Hz, 1H), 6.94 (dd,
 $J=8.7, 1.5$ Hz, 1H), 7.24 (s, 1H).

Zinc combretastatin A-4 3'-O-phosphate (5f)

Collection of the white solid and washing with acetone gave a colorless,
25 opalescent solid (164 mg): m.p. 198-200°C; $^1\text{H-NMR}$ (300 MHz, D_2O) δ 3.58
(s, 6H, 2 x OCH_3), 3.65 (s, 3H, OCH_3), 3.73 (s, 3H, OCH_3), 6.41 (d, $J=12$ Hz,
1H), 6.52 (s, 2H), 6.52 (d, $J=12$ Hz, 1H), 6.82 (d, $J=8.1$ Hz, 1H), 6.89 (dd,
 $J=8.1, 1.4$ Hz, 1H), 7.12 (d, $J=1.4$ Hz, 1H).

Method B (Prodrugs 5g-l)

5

The same general procedure as described above was used, except 2 equivalents of a 1.0 M solution of the amine in dry methanol was added and the reaction mixture allowed to stir for 8 h. All the amine salts were recrystallized from methanol-ether.

10

Imidazole combretastatin A-4 3'-O-phosphate (5g)

Recrystallization gave 137 mg: m.p. 196-198°C; ¹H-NMR (300 MHz, D₂O) δ 3.66 (s, 6H, 2 x OCH₃), 3.73 (s, 3H, OCH₃), 3.82 (s, 3H, OCH₃), 6.47 (d, J=12 Hz, 1H), 6.58 (s, 2H), 6.59 (d, J=12 Hz, 1H), 6.92 (dd, J=8.4, 1.2 Hz, 1H), 7.23 (d, J=1.2 Hz, 1H), 7.46 (s, 2H, δ4, δ5), 8.67 (s, 1H, δ2).

15

Morpholine combretastatin A-4 3'-O-phosphate (5h)

Recrystallization afforded (121 mg 61% yield): m.p. 209-210°C; ¹H-NMR (300 MHz, D₂O) δ 3.22 (m, 4H, -CH₂OCH₂-), 3.46 (s, 6H, OCH₃), 3.48 (s, 3H, OCH₃), 3.54 (s, 3H, OCH₃), 3.88 (m, 4H, -CH₂NCH₂-), 6.36 (d, J=12.3 Hz, 1H), 6.49 (s, 2H), 6.50 (d, J=12.3 Hz, 1H), 6.79 (dd, J=8.1, 1.2 Hz, 1H), 7.24 (bd, 8.1 Hz, 1H), 7.40 (bd, J=1.2 Hz, 1H).

20

Piperazine combretastatin A-4 3'-O-phosphate (5i)

Following recrystallization 151 mg: m.p. 198-200°C; ¹H-NMR (300 MHz, CD₃OD) δ 3.01 (bs, 1H, NH), 3.52 (bm, 8H, δ2-H), 3.67 (s, 6H, 2 x OCH₃), 3.74 (s, 3H, OCH₃), 3.83 (s, 3H, OCH₃), 6.49 (d, J=12 Hz, 1H), 6.56 (d, J=12 Hz, 1H), 6.62 (s, 2H), 6.95 (m, 2H), 7.24 (s, 1H).

25

Piperidine combretastatin A-4 3'-O-phosphate (5j)

By recrystallization 137 mg (was collected): m.p. = 159-160°C; ¹H-NMR (300 MHz, D₂O) δ 1.67 (m, 8H, [2 x δ3 H s]), 1.77 (m, 4H, [2 x δ4 H s]), 3.15 (m, 8H, [2 x δ2 H s]), 3.66 (s, 6H, 2 x OCH₃), 3.73 (s, 3H, OCH₃), 3.82 (s, 3H, OCH₃), 6.48 (d, J=12 Hz, 1H), 6.60 (s, 2H), 6.61 (d, J=12 Hz, 1H), 6.854 (d, J=8.5 Hz, 1H), 6.92 (dd, J=19.5, 8.5 Hz, 1H), 7.26 (s, 1H).

Pyrazole combretastatin A-4 3'-O-phosphate (5k)

Recrystallization produced 112 mg: m.p. = 186-187°C; ¹H-NMR (300 MHz, D₂O) δ 3.69 (s, 6H, 2 x OCH₃), 3.76 (s, 3H, OCH₃), 3.85 (s, 3H, OCH₃), 6.30 (d, J=1.4 Hz, 2H, 2 x δ₄), 6.53 (d, J=12 Hz, 1H), 6.63 (d, J=12 Hz, 1H), 6.64 (s, 2H), 6.97 (m, 2H), 7.25 (d, J=1.8 Hz, 1H), 7.67 (d, 4H, 2 x δ₃, δ₅ H).

5

Pyridine combretastatin A-4 3'-O-phosphate (5l)

The yield was 96 mg: m.p. = 165-168°C; ¹H-NMR (300 MHz, D₂O) δ 3.66 (s, 6H, 2 x OCH₃), 3.73 (s, 3H, OCH₃), 7.82 (s, 3H, OCH₃), 6.48 (d, J=12 Hz, 1H), 6.58 (s, 2H), 6.59 (d, J=12 Hz, 1H), 6.90 (d, J=8.4 Hz, 1H), 6.95 (dd, J=8.4, 1.5 Hz, 1H), 7.22 (bd, J=1.5 Hz, 1H), 7.47 (d, J=3.3 Hz, 4H, 2 x δ_{3,5}-H), 8.0 (m, 2H, δ₄-H), 8.86 (m, 4H, 2 x δ_{2,6}-H).

10

Method C (Prodrugs 5m-s)

15

An analogous method as summarized for prodrugs 3a-f was used, except that two equivalents of the alkaloid or other base in the appropriate solvent were added to the phosphoric acid in the same solvent. Recrystallization/precipitation was accomplished using methanol-ether.

Adenosine combretastatin A-4 3'-O-phosphate (5m)

20

The adenosine salt weighed 160 mg: m.p. 155-158°C; ¹H-NMR (300 MHz, D₂O) δ 3.50 (s, 6H, 2 x OCH₃), 3.57 (s, 3H, OCH₃), 3.68 (s, 3H, OCH₃), 3.71 (d, J=2.1 Hz, 2H), 3.76 (bs, 2H), 3.80 (dd, J=2.1, 6.6 Hz, 1H), 4.14 (d, J=3.0 Hz, 2H), 4.28 (t, J=3.0 Hz, 2H), 4.58 (t, J=6.0 Hz, 2H), 5.85 (d, J=6.0 Hz, 2H), 6.21 (d, J=12.0 Hz, 1H), 6.32 (s, 2H), 6.36 (d, J=12.6 Hz, 1H), 6.71 (bs, 3H), 7.07 (s, 1H), 7.95 (d, J=1.5 Hz, 2H), 8.11 (s, 2H).

25

Cinchonine combretastatin A-4 3'-O-phosphate (5n)

The use of cinchonine led to 175 mg of product, m.p. 189-193°C; ¹H-NMR (300 MHz, CDCl₃) δ 0.829 (m, 1H), 1.21 (m, 1H), 1.74 (m, 1H), 2.15 (t, J=12 Hz, 1H), 2.32 (q, 1H), 3.30 (br s, -OH, 1H), 3.6 (s, 3H, OCH₃), 3.64 (s, 6H, 2 x OCH₃), 3.78 (s, 3H, OCH₃), 4.45 (t, J=9.3 Hz, 1H), 5.18 (d, J=16

Hz, 1H), 5.23 (d, $J=10.8$ Hz, 1H), 5.42 (d, $J=12$ Hz, 1H), 5.87 (m, 1H), 7.7 (d, $J=8.4$ Hz, 1H), 7.76 (d, $J=6.3$ Hz, 1H), 7.86 (d, $J=4.5$ Hz, 1H), 7.97 (d, $J=8.7$ Hz, 1H), 8.10 (d, $J=8.7$ Hz, 1H), 8.29 (d, $J=8.4$ Hz, 1H), 8.83 (d, $J=4.5$ Hz, 1H):

5

Glucosamine combretastatin A-4 3'-O-phosphate (5o)

Recrystallization led to 98 mg of product, m.p. 190-195°C (dec); 1 H-NMR (300 MHz, CD₃OD) δ 1.81 (s), 1.88 (s), 1.93 (s), 2.85 (s), 2.88 (d, $J=2.1$ Hz, 1H), 2.91 (s, 1H), 3.16 (d, $J=3.9$ Hz, 1H), 3.19 (d, $J=3.9$ Hz, 1H), 3.38 (h, 2H), 3.53-3.82 (m, 4H), 3.64 (s, 3H, OCH₃), 3.69 (s, 3H, OCH₃), 3.74 (s, 6H, 2 x OCH₃), 4.82 (d, $J=8.1$ Hz, 1H), 5.33 (d, $J=3.3$ Hz, 1H), 6.51 (d, $J=12.1$ Hz, 1H), 6.60 (d, $J=12.1$ Hz, 1H), 6.63 (s, 2H), 6.80-7.22 (m, 3H).

10

Quinine combretastatin A-4 3'-O-phosphate (5p)

Recrystallization of the quinine salt gave 75 mg: m.p. 179-184°C; 1 H-NMR (300 MHz, CD₃OD) δ 3.00 (q, 10.1, 13.7 Hz, 1H), 3.15 (o, $J=5.0$, 8.9, 8.9 Hz, 1H), 3.37 (h, $J=3.0$, 5.3, 10.1, 13.2 Hz, 1H), 3.41 (bs, 1H, OH), 3.61 (s, 3H, OCH₃), 3.69 (s, 3H, OCH₃), 3.82 (s, 6H, 2 x OCH₃), 3.91 (s, 3H, OCH₃), 4.90 (d, $J=10.0$ Hz, 1H), 4.97 (d, $J=17.1$ Hz, 1H), 5.50 (d, $J=4.4$ Hz, 1H), 5.84 (o, $J=7.6$, 10.0, 17.3 Hz, 1H), 6.55 (bd, $J=12.6$ Hz, 1H), 6.61 (bd, $J=12.6$ Hz, 1H), 6.63 (s, 2H), 6.67 (bs, 3H), 7.22 (s, 1H), 7.34 (d, $J=9.5$ Hz, 1H), 7.50 (d, $J=4.3$ Hz, 1H), 8.70 (d, $J=4.2$ Hz, 1H).

15

Quinidine combretastatin A-4 3'-O-phosphate (5q)

Quinidine was used to prepare 300 mg of product, m.p. 180-181°C; 1 H-NMR (300 MHz, CD₃OD) δ 0.963 (t, 1H), 1.16 (m, 1H), 1.89 (m, 2H), 1.99 (bs, 1H), 2.34 (t, $J=6.8$ Hz, 1H), 2.65 (dd, $J=6.6$ Hz, 12.3 Hz, 1H), 3.10 (s, 1H), 3.22 (m, 1H), 3.29 (o, $J=1.6$, 7.9, 14 Hz), 3.32 (s, 3H, OCH₃), 3.65 (s, 3H, OCH₃), 3.99 (s, 3H, OCH₃), 4.09 (s, 6H, 2 x OCH₃), 4.61 (bs, 1H), 5.10 (d, $J=9.3$ Hz), 5.28 (d, $J=15.4$ Hz, 1H), 5.96 (bs, 1H), 6.11 (o, $J=7.4$, 10.5, 16.0 Hz, 1H), 6.54 (bd, $J=12.0$ Hz, 1H), 6.60 (bd, $J=12$ Hz, 1H), 6.61 (s, 2H), 7.43 (dd, $J=6.9$, 1.8 Hz, 1H), 7.56 (dd, $J=7.2$, 1.8 Hz, 1H), 7.61 (d,

20

25

J=1.8 Hz), 7.70 (t, *J*=3.3 Hz, 1H), 7.91 (d, *J*=4.4 Hz, 1H), 7.97 (d, *J*=9.2 Hz, 1H), 8.06 (d, *J*=9.2 Hz, 1H), 8.69 (d, *J*=4.4 Hz, 1H), 8.79 (d, *J*=4.8 Hz, 1H).

Tetracycline combretastatin A-4 3'-O-phosphate (5r)

The tetracycline salt upon recrystallization weighed 136 mg: m.p. 191-193°C; ¹H-NMR (300 MHz, DMSO-d₆) δ 1.53-3.21 (m, 4H, C₄α and C₅α methine protons, C₅-methylene hydrogens), 1.56 (s, 3H, C₆-CH₃), 2.55 (s, 6H, N(CH₃)₂), 3.31 (bs, 1H, C₄-H), 3.64 (s, 6H, 2xOCH₃), 3.67 (s, 3H, OCH₃), 3.72 (s, 3H, OCH₃), 4.31 (bs, 1H, C₄-H), 6.41 (d, *J*=12.6, 1H), 6.49 (d, *J*=12.6, 1H), 6.61 (s, 2H), 6.87 (s, 3H), 6.93 (d, *J*=8.1, 1H, D-Ar-H), 7.14 (d, *J*=7.8, 1H, D-Ar-H), 7.47 (s, 1H), 7.56 (t, *J*=7.8, 1H, D-Ar-H), 9.13 (bs, 2H, CONH₂), 11.7 (bs, 1H, C₁₀-OH).

Verapamil combretastatin A-4 3'-O-phosphate (5s)

From verapamil was obtained 110 mg of product: m.p. 185-186°C; ¹H-NMR (300 MHz, CD₃OD) δ 0.73 (d, *J*=6.6 Hz, 3H), 1.15 (d on m, *J*=6.6 Hz, 4H), 1.32 (m, 1H), 1.65 (m, 1H), 1.99 (s, 1H), 2.17 (m, 1H), 2.19 (s, 1H), 2.78 (bs, 2H), 3.11 (m, 2H), 3.27 (bs, 2H), 3.36 - 3.82 (4s, 8 x OCH₃, 24H), 6.47 (d, *J*=12 Hz, 1H), 6.57 (d, *J*=12Hz, 1H), 6.64 (bd, 1H), 6.80 (bd, 1H), 6.92 (dd, *J*=8.4, 1.9 Hz, 2H), 7.28 (s, 1H).

Biological Results

All of the synthetic products were evaluated against a minipanel of human cancer cell lines, the murine P388 lymphocytic leukemia and a selection of microorganisms. These results are summarized in Tables I-III respectively.

In the case of Antimicrobial susceptibility testing compounds were screened against the bacteria *Stenotrophomonas maltophilia*, *Micrococcus luteus*, *Staphylococcus aureus*, *Escherichia coli*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Streptococcus pneumoniae*, *Neisseria gonorrhoeae*, and the fungi *Candida albicans* and *Cryptococcus neoformans*, according to established disk susceptibility testing protocols (National Committee for Clinical Laboratory Standards, 1997).

Table I. Human Cancer Cell Line Activity (GI_{50} (μ g/ml)) and Murine P-388 Leukemia Inhibitory Activity (ED_{50} (μ g/ml)) of combretastatin A-4 (**1a**) and synthetic modifications (**4a-5s**).

5

	Structure	Prostate	Pharynx	Lung-NSC	Thyroid
		DU-145	FADU	NCI-H460	SW1736
10	1a	0.00076	0.00065	0.00056	0.00071
	3d	0.0072	0.0045	0.0035	0.0061
	4a	0.037	0.040	0.038	0.080
	4c	0.044	0.071	0.038	11.2
	5a	0.001	0.001	0.001	0.010
	5b	0.0028	0.0023	0.0032	8.4
15	5c	0.0025	0.003	0.004	0.030
	5d	0.01	0.031	0.017	6.8
	5e	<0.001	0.00091	0.0015	14.7
	5f	0.0062	0.0070	0.0074	0.059
	5g	0.001	0.01	0.004	0.011
	5h	0.0024	0.0016	0.003	0.02
20	5i	0.0011	0.0018	0.0028	23.5
	5j	0.01	0.01	0.01	0.50
	5k	0.01	0.01	0.01	4.6
	5l	0.036	0.032	0.038	0.01
	5m	0.036	0.032	0.038	0.092
	5n	0.030	0.024	0.037	0.089
25	5o	0.026	0.015	0.034	0.061
	5p	0.0048	0.006	0.0042	7.5
	5q	0.0036	0.0033	0.0039	0.11
	5r	0.058	0.0055	0.0046	0.012
	5s	0.0036	0.0046	0.004	0.0061

* Not tested against this cell line

35

Table I.(continued)

5	Structure	Neuroblast	Pancreas	Melanoma	P-388
		SK-N-SH	BXPC-3	SK-Mel-3	
10	1a	0.00026	>0.1	0.00020	0.00266
	3d	0.0025	0.23	NT*	0.00292
	4a	0.029	3.9	NT*	0.280
	4c	3.1	4.0	0.036	0.02
	5a	0.015	0.22	0.0036	0.0011
	5b	0.011	0.31	0.0043	0.001
	5c	0.016	0.31	NT*	0.0012
	5d	0.01	0.43	NT*	0.0018
	5e	0.014	0.20	0.0036	0.016
	5f	0.024	1.1	1.0	0.0343
15	5g	0.01	0.39	0.01	0.0025
	5h	0.039	0.26	0.0042	0.0023
	5i	0.021	0.19	0.0036	0.0016
	5j	0.017	0.30	0.01	0.0029
	5k	0.014	0.23	0.01	0.0023
	5l	0.03	11.6	0.35	<0.001
20	5m	0.034	11.6	0.35	0.16
	5n	NT*	1.6	NT*	0.020
	5o	0.016	4.5	NT*	0.0164
	5p	NT*	2.2	NT*	0.027
	5q	NT*	0.43	NT*	0.0032
	5r	0.0032	0.57	NT*	0.037
25	5s	0.0025	0.46	NT*	0.001

* Not tested against this cell line

Table II. Antimicrobial activity of combretastatin A-4 (**1a**), combretastatin A-4 Prodrug (**3d**) and synthetic modifications (**4a**, **4c**, **5a-s**).

	Compound	Microbe(s) inhibited	Minimum inhibitory concentration (μ g/disk)
5	1a	<i>Neisseria gonorrhoeae</i>	25-50
10	3d	<i>Neisseria gonorrhoeae</i>	50-100
	4a	<i>Micrococcus luteus</i>	25-50
	4c	<i>Neisseria gonorrhoeae</i>	50-100
	5a	*	
	5b	*	
15	5c	*	
	5d	*	
	5e	<i>Neisseria gonorrhoeae</i>	6.25-12.5
		<i>Candida albicans</i>	25-50
		<i>Cryptococcus neoformans</i>	12.5-25
20	5f	*	
	5g	*	
	5h	*	
	5i	<i>Neisseria gonorrhoeae</i>	25-50
		<i>Candida albicans</i>	50-100
		<i>Cryptococcus neoformans</i>	25-50
25	5j	*	
	5k	*	
	5l	*	
	5m	*	
30	5n	<i>Neisseria gonorrhoeae</i>	25-50
	5o	*	
	5p	*	
	5q	<i>Neisseria gonorrhoeae</i>	6.25-12.5
	5r	<i>Neisseria gonorrhoeae</i>	3.12-6.25
35		<i>Escherichia coli</i>	3.12-6.25
		<i>Stenotrophomonas maltophilia</i>	6.25-12.5
		<i>Enterobacter cloacae</i>	3.12-6.25
		<i>Micrococcus luteus</i>	0.78-1.56
		<i>Streptococcus pneumoniae</i>	0.195-0.39
40		<i>Staphylococcus aureus</i>	0.195-0.39
		<i>Enterococcus faecalis</i>	25-50
	5s	*	

*At 100 μ g/disk no inhibition of the eight bacteria and two fungi tested.

Table III. Solubility of combretastatin A-4 prodrug **3d**, (E)-stilbene prodrug **4c** and structural modifications **5a-s** in mg per 1 ml water at 25°C.

5

Compound	3d	4c	5a	5b	5c	5d	5e	5f	5g	5h
Solubility (mg/ml)	20	4	2	>50	6	7	3	11	10	9

10

Table III. (continued)

15

Compound	5i	5j	5k	5l	5m	5n	5o	5p	5q	5r	5s
Solubility (mg/ml)	1	5	8	3	4	4	15	6	2	1	16

20

Combretastatin A-4, combretastatin A-4 prodrug and several prodrug modifications inhibited growth of the pathogenic bacterium *Neisseria gonorrhoeae* (Table II). Addition of manganese **5e** and piperazine **5i** to the parent phosphate yielded compounds inhibitory to opportunistic fungi. As expected, the tetracycline derivative **5r** inhibited the growth of all Gram-negative and Gram-positive bacteria tested.

Biological Evaluation and Statistical Definitions

The following measures are used to express drug activity by giving the drug dose which reduces cell growth to a specified percentage of growth:

ED₅₀ (P388) and **GI₅₀** (HTCL) are the drug doses (in $\mu\text{g}/\text{ml}$ of cancer cells) needed to reduce the cancer cells by 50%. There is no mathematical difference between **ED₅₀** and **GI₅₀**, which are both calculated using the same formula. The only difference is historical usage.

Total Growth Inhibition ("TGI") is the drug dose (in $\mu\text{g}/\text{ml}$ of cancer cells) needed to yield zero percent growth. Whether just as many cells were killed as were produced (steady state), or no growth occurred (total inhibition), cannot be distinguished.

Lethal Concentration 50% ("LC₅₀") is the drug concentration (in $\mu\text{g}/\text{ml}$ of cancer cells) kills half of the cells originally present at the beginning of the experiment.

Each drug is tested at five (5) doses: 100 - 10 - 1 - 0.1 - 0.01 $\mu\text{g}/\text{ml}$.
5 Percent Growths are calculated for each dose. The two (or three) doses with growth values above, below, (or near to) 50% growth are used to calculate the ED₅₀/GI₅₀ using a linear regression formula. The log of the dose is used during the regression computation. If no dose yields a growth value under 50%, the results are expressed as: ED₅₀ > (highest dose). If no dose yields growth
10 higher than 50% growth, then ED₅₀ < (lowest dose). Similar calculations are performed for the TGI at 0% growth, and at -50% growth for the LC₅₀.

PERCENT OF GROWTH

At the start of an experiment, cells from the in vitro cell cultures are inoculated into the appropriate tubes or microtiter plates. One set of control tubes/plates is immediately counted to determine the number of cells at the
15 start of the experiment. This is the "baseline count", or "T_{zero} reading". At the end of the experiment (48 hours later) a second set of control tubes/plates is analyzed to determine the "Control Growth" value. The growth (or death) of cells relative to the initial quantity of cells is used to define the "Percent of
20 Growth".

5

100% Growth = Control Growth

100% Growth = 200

10

50% Growth = $T_{\text{zero}} + \frac{\text{Control}-T_{\text{zero}}}{2}$

50% Growth = 110

0% Growth = T_{zero}

0% Growth = 20

-50% Growth = $T_{\text{zero}} / 2$

-50% Growth = 10

20

15 For further information about the testing protocols and procedures see Anne Monks et al., "Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines", 83 J. Nat. Cancer Inst., No. 11, pp. 757-66 (5 June 1991) and Michael J. Boyd, "Status of the NCI Preclinical Antitumor Drug Discovery Screen", 3 Princ. & Practice of Oncology Updates, No. 10, pp. 1-12 (Oct. 1989).

25

By definition a "prodrug" is a precursor which will undergo metabolic activation in vivo to the active drug. Thus, certain phosphate derivatives make ideal prodrugs if the phosphate group can be cleaved by endogenous non-specific phosphatases (McComb et al., Alkaline Phosphatase, New York: Plenum Press, 1979) As previously reported (See, U.S. Patent Nos. 4,996,237 and 5,561,122), a preliminary in vitro comparison of the stable combretastatin A-4 phosphate metal or ammonium salts against the P388 murine leukemia and a selection of six human tumor cell lines (OVCAR-3, SF-295, A498, NCI-H460, KM20L2, SK-MEL-5) was performed using the sulforhodamine B assay (Skehan et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," J. Nat. Cancer Inst., 1107 (1990)). Again, sodium phosphate derivative **3d** is an equivalent to the derivative **1h** disclosed earlier. The assay results relative to **1h** will thus be repeated here with respect to **3d**. Combretastatin A-4 **1a** and prodrug **1h** (**3d**) were then comparatively evaluated against the full-panel NCI

EXAMPLE:

Baseline Count = 20
 Control Count = 200
 (10-Fold Growth)

screen (Boyd, "Status of the NCI Preclinical Antitumor Drug Discovery Screen: Implications for Selection of New Agents for Clinical trial," 3 Cancer: Principles and Practice of Oncology Updates, No. 10, pp. 1-12 (1989); and Boyd et al., "The Future of New Drug Development, Section I, Introduction to Cancer Therapy," Current Therapy in Oncology, Philadelphia: Decker (1993)). Both were tested in quadruplicate at each of three different concentration ranges (10^{-5} , 10^{-6} and 10^{-7} M upper limits, five, \log_{10} -spaced concentrations in each range). Optimal tests were selected for overall potency and differential cytotoxicity comparisons (Boyd and Paul, "Some Practical Considerations and Applications of the NCI *in vitro* Anticancer Drug Discovery Screen," Drug Development Research, (In Press)). The mean panel GI_{50} concentration for the parent compound 1a was $6.61 \pm 0.79 \times 10^{-9}$ M, compared to $6.89 \pm 0.96 \times 10^{-9}$ M for prodrug 1h (3d). TGI-COMPARE analyses (*Id.*) revealed a very high Pearson correlation coefficient of 0.91 for the differential cytotoxicity profiles of combretastatin A-4 1a and its prodrug 1h (3d). This high correlation coefficient reflects similarities in biological properties and/or chemical structure and properties. Paull *et al.*, "Display and analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm," 81 J. Nat. Cancer Inst., No. 14, pp. 108-92 (July 19, 1989).

Clearly, the excellent water solubility of sodium phosphate 1h (3d), good stability and cell growth inhibitory activity comparable to combretastatin 1a allowed selection of this prodrug candidate for drug formulation studies. In a like manner, it is believed that any of the combretastatin A-4 phosphate metal or ammonium salts can be synthesized and utilized as prodrugs with cell growth inhibitory activity comparable to combretastatin 1a.

Based upon the foregoing, compositions 1h (3d) are believed useful in the treatment of one or more neoplastic diseases. For example, acute myelocytic leukemia, acute lymphocytic leukemia, malignant melanoma, adenocarcinoma of lung, neuroblastoma, small cell carcinoma of the lung, breast carcinoma, colon carcinoma, ovarian carcinoma, bladder carcinoma, and the like.

The dosage administered will be dependent upon the identity of the neoplastic disease; the type of host involved, including its age, health and

weight; the kind of concurrent treatment, if any; the frequency of treatment and therapeutic ratio.

5

Illustratively, dosage levels of the administered active ingredients are: intravenous, 0.1 to about 20 mg/kg; intramuscular, 1 to about 50 mg/kg; orally, 5 to about 100 mg/kg; intranasal instillation, 5 to about 100 mg/kg; and aerosol, 5 to about 100 mg/kg of host body weight.

10

Expressed in terms of concentration, an active ingredient can be present in the compositions of the present invention for localized use about the cutis, intranasally, pharyngolaryngeally, bronchially, intravaginally, rectally, or ocularly in a concentration of from about 0.01 to about 50% w/w of the composition; preferably about 1 to about 20% w/w of the composition; and for parenteral use in a concentration of from about 0.05 to about 50% w/v of the composition and preferably from about 5 to about 20% w/v.

15

The compositions of the present invention are preferably presented for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, suppositories, sterile parenteral solutions or suspensions, sterile non-parenteral solutions of suspensions, and oral solutions or suspensions and the like, containing suitable quantities of an active ingredient.

20

For oral administration either solid or fluid unit dosage forms can be prepared.

25

Powders are prepared quite simply by comminuting the active ingredient to a suitably fine size and mixing with a similarly comminuted diluent. The diluent can be an edible carbohydrate material such as lactose or starch. Advantageously, a sweetening agent or sugar is present as well as a flavoring oil.

30

Capsules are produced by preparing a powder mixture as hereinbefore described and filling into formed gelatin sheaths. Advantageously, as an adjuvant to the filling operation, a lubricant such as talc, magnesium stearate, calcium stearate and the like is added to the powder mixture before the filling operation.

Soft gelatin capsules are prepared by machine encapsulation of a slurry of active ingredients with an acceptable vegetable oil, light liquid petrolatum or other inert oil or triglyceride.

5

10

15

20

25

30

Tablets are made by preparing a powder mixture, granulating or slugging, adding a lubricant and pressing into tablets. The powder mixture is prepared by mixing an active ingredient, suitably comminuted, with a diluent or base such as starch, lactose, kaolin, dicalcium phosphate and the like. The powder mixture can be granulated by wetting with a binder such as corn syrup, gelatin solution, methylcellulose solution or acacia mucilage and forcing through a screen. As an alternative to granulating, the powder mixture can be slugged, i.e., run through the tablet machine and the resulting imperfectly formed tablets broken into pieces (slugs). The slugs can be lubricated to prevent sticking to the tablet-forming dies by means of the addition of stearic acid, a stearic salt, talc or mineral oil. The lubricated mixture is then compressed into tablets.

Advantageously, the tablet can be provided with a protective coating consisting of a sealing coat or enteric coat of shellac, a coating of sugar and methylcellulose and polish coating of carnauba wax.

Fluid unit dosage forms for oral administration such as in syrups, elixirs and suspensions can be prepared wherein each teaspoonful of composition contains a predetermined amount of an active ingredient for administration. The water-soluble forms can be dissolved in an aqueous vehicle together with sugar, flavoring agents and preservatives to form a syrup. An elixir is prepared by using a hydroalcoholic vehicle with suitable sweeteners together with a flavoring agent. Suspensions can be prepared of the insoluble forms with a suitable vehicle with the aid of a suspending agent such as acacia, tragacanth, methylcellulose and the like.

For parenteral administration, fluid unit dosage forms are prepared utilizing an active ingredient and a sterile vehicle, water being preferred. The active ingredient, depending on the form and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the water-soluble active ingredient can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampule and sealing. Advantageously, adjuvants such as a local anesthetic, preservative and buffering agents can be dissolved in the vehicle. Parenteral suspensions are prepared in substantially the same manner except that an active ingredient is suspended in the vehicle

5

instead of being dissolved and sterilization cannot be accomplished by filtration. The active ingredient can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active ingredient.

10

In addition to oral and parenteral administration, the rectal and vaginal routes can be utilized. An active ingredient can be administered by means of a suppository. A vehicle which has a melting point at about body temperature or one that is readily soluble can be utilized. For example, cocoa butter and various polyethylene glycols (Carbowaxes) can serve as the vehicle.

15

For intranasal instillation, a fluid unit dosage form is prepared utilizing an active ingredient and a suitable pharmaceutical vehicle, preferably P.F. water, a dry powder can be formulated when insufflation is the administration of choice.

20

For use as aerosols, the active ingredients can be packaged in a pressurized aerosol container together with a gaseous or liquified propellant, for example, dichlorodifluoromethane, carbon dioxide, nitrogen, propane, and the like, with the usual adjuvants such as cosolvents and wetting agents, as may be necessary or desirable.

25

The term "unit dosage form" as used in the specification and claims refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical diluent, carrier or vehicle. The specifications for the novel unit dosage forms of this invention are dictated by and are directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitation inherent in the art of compounding such an active material for therapeutic use in humans, as disclosed in this specification, these being features of the present invention.

30

Examples of suitable unit dosage forms in accord with this invention are tablets, capsules, troches, suppositories, powder packets, wafers, cachets, teaspoonfuls, tablespoonfuls, dropperfuls, ampules, vials, segregated multiples of any of the foregoing, and other forms as herein described.

5

10

15

20

25

30

The active ingredients to be employed as antineoplastic agents can be easily prepared in such unit dosage form with the employment of pharmaceutical materials which themselves are available in the art and can be prepared by established procedures. The following preparations are illustrative of the preparation of the unit dosage forms of the present invention, and not as a limitation thereof. Several dosage forms were prepared embodying the present invention. They are shown in the following examples in which the notation "active ingredient" signifies either of the combretastatin A-4 phosphate metal or ammonium salts, e.g. **3d**, or structural modifications **4a**, **4c** and/or **5a-s**.

COMPOSITION "A"

Hard-Gelatin Capsules

One thousand two-piece hard gelatin capsules for oral use, each capsule containing 200 mg of an active ingredient are prepared from the following types and amounts of ingredients:

Active ingredient, micronized	200 g
Corn Starch	20 g
Talc	20 g
Magnesium stearate	2 g

The active ingredient, finely divided by means of an air micronizer, is added to the other finely powdered ingredients, mixed thoroughly and then encapsulated in the usual manner.

The foregoing capsules are useful for treating a neoplastic disease by the oral administration of one or two capsules one to four times a day.

Using the procedure above, capsules are similarly prepared containing an active ingredient in 50, 250 and 500 mg amounts by substituting 50 g, 250 g and 500 g of an active ingredient for the 200 g used above.

COMPOSITION "B"

Soft Gelatin Capsules

One-piece soft gelatin capsules for oral use, each containing 200 mg of an active ingredient, finely divided by means of an air micronizer, are prepared

by first suspending the compound in 0.5 ml of corn oil to render the material capsulatable and then encapsulating in the above manner.

The foregoing capsules are useful for treating a neoplastic disease by the oral administration of one or two capsules one to four times a day.

5

COMPOSITION "C"

Tablets

One thousand tablets, each containing 200 mg of an active ingredient, are prepared from the following types and amounts of ingredients:

	Active ingredient, micronized	200 g
10	Lactose	300 g
	Corn starch	50 g
	Magnesium stearate	4 g
	Light liquid petrolatum	5 g

10

The active ingredient, finely divided by means of an air micronizer, is added to the other ingredients and then thoroughly mixed and slugged. The slugs are broken down by forcing them through a Number Sixteen screen. The resulting granules are then compressed into tablets, each tablet containing 200 mg of the active ingredient.

15

The foregoing tablets are useful for treating a neoplastic disease by the oral administration of one or two tablets one to four times a day.

20

Using the procedure above, tablets are similarly prepared containing an active ingredient in 250 mg and 100 mg amounts by substituting 250 g and 100 g of an active ingredient for the 200 g used above.

COMPOSITION "D"

25

Oral Suspension

One liter of an aqueous suspension for oral use, containing in each teaspoonful (5 ml) dose, 50 mg of an active ingredient, is prepared from the following types and amounts of ingredients:

	Active ingredient, micronized	10 g
30	Citric acid	2 g
	Benzoic acid	1 g
	Sucrose	790 g
	Tragacanth	5 g

Lemon Oil 2 g

Deionized water, q.s. 1000 ml

The citric acid, benzoic acid, sucrose, tragacanth and lemon oil are dispersed in sufficient water to make 850 ml of suspension. The active 5 ingredient, finely divided by means of an air micronizer, is stirred into the syrup unit uniformly distributed. Sufficient water is added to make 1000 ml.

The composition so prepared is useful for treating a neoplastic disease at a dose of 1 teaspoonful (15 ml) three times a day.

COMPOSITION "E"

10 Parenteral Product

A sterile aqueous suspension for parenteral injection, containing 30 mg of an active ingredient in each milliliter for treating a neoplastic disease, is prepared from the following types and amounts of ingredients:

15	Active ingredient, micronized	30 g
	POLYSORBATE 80	5 g
	Methylparaben	2.5 g
	Propylparaben	0.17 g
	Water for injection, q.s. 1000 ml.	

20 All the ingredients, except the active ingredient, are dissolved in the water and the solution sterilized by filtration. To the sterile solution is added the sterilized active ingredient, finely divided by means of an air micronizer, and the final suspension is filled into sterile vials and the vials sealed.

25 The composition so prepared is useful for treating a neoplastic disease at a dose of 1 milliliter (1ml) three times a day.

COMPOSITION "F"

Suppository, Rectal and Vaginal

30 One thousand suppositories, each weighing 2.5 g and containing 200 mg of an active ingredient are prepared from the following types and amounts of ingredients:

30	Active ingredient, micronized	15 g
	Propylene glycol	150 g
	Polyethylene glycol #4000, q.s.	2,500 g

5

The active ingredient is finely divided by means of an air micronizer and added to the propylene glycol and the mixture passed through a colloid mill until uniformly dispersed. The polyethylene glycol is melted and the propylene glycol dispersion is added slowly with stirring. The suspension is poured into unchilled molds at 40°C. The composition is allowed to cool and solidify and then removed from the mold and each suppository foil wrapped.

The foregoing suppositories are inserted rectally or vaginally for treating a neoplastic disease.

10

COMPOSITION "G"

Intranasal Suspension

One liter of a sterile aqueous suspension for intranasal instillation, containing 20 mg of an active ingredient in each milliliter, is prepared from the following types and amounts of ingredients:

15

Active ingredient, micronized	15 g
POLYSORBATE 80	5 g
Methylparaben	2.5 g
Propylparaben	0.17 g
Deionized water, q.s. 1000 ml.	

20

All the ingredients, except the active ingredient, are dissolved in the water and the solution sterilized by filtration. To the sterile solution is added the sterilized active ingredient, finely divided by means of an air micronizer, and the final suspension is aseptically filled into sterile containers.

The composition so prepared is useful for treating a neoplastic disease, by intranasal instillation of 0.2 to 0.5 ml given one to four times per day.

25

An active ingredient can also be present in the undiluted pure form for use locally about the cutis, intranasally, pharyngolaryngeally, bronchially, or orally.

COMPOSITION "H"

Powder

30

Five grams of an active ingredient in bulk form is finely divided by means of an air micronizer. The micronized powder is placed in a shaker-type container.

The foregoing composition is useful for treating a neoplastic disease, at localized sites by applying a powder one to four times per day.

COMPOSITION "I"

Oral Powder

5 One hundred grams of an active ingredient in bulk form is finely divided by means of an air micronizer. The micronized powder is divided into individual doses of 200 mg and packaged.

10 The foregoing powders are useful for treating a neoplastic disease, by the oral administration of one or two powders suspended in a glass of water, one to four times per day.

COMPOSITION "J"

Insufflation

One hundred grams of an active ingredient in bulk form is finely divided by means of an air micronizer.

15 The foregoing composition is useful for treating a neoplastic disease, by the inhalation of 300 mg one to four times a day.

* * *

20 From the foregoing, it becomes readily apparent that new and useful antineoplastic drugs and new and useful antineoplastic preparations based thereupon have been herein described and illustrated which fulfill all of the aforestated objectives in a remarkably unexpected fashion. It is of course understood that such modifications, alterations and adaptations as will readily occur to the artisan confronted with this disclosure are intended within the spirit of the present invention as defined by the following claims.

Claims

1. The method of synthesizing combretastatin A-4 prodrugs and trans-combretastatin A-4 prodrugs comprising:

5 admixing combretastatin A-4 with a phosphorylating agent to form a phosphate ester of combretastatin A-4 having protective groups thereupon;

10 selectively cleaving said phosphate ester protective groups with iodotrimethylsilane to yield a phosphoric acid derivative of combretastatin A-4; and

15 treating said phosphoric acid derivative of combretastatin A-4 with sodium methoxide to yield combretastatin A-4 Prodrug or a trans-isomer thereof as the ultimate product.

20 2. The method according to Claim 1 in which said phosphorlating agent is selected from the group consisting of dibenzyl phosphite/carbon tetrachloride, di-tert-butyloxy (N,N-diethylamido) phosphine and bis[2-(trimethylsilyl)ethoxy]N,N-diisopropylamidophosphine.

25 3. The method of Claim 1 in which said cleaving agent is selected from the group consisting of: iodotrimethylsilane, trifluoracetic acid, and tetrabutylammonium fluoride.

30 4. The method of Claim 2 in which said cleaving agent is selected from the group consisting of: iodotrimethylsilane, trifluoracetic acid, and tetrabutylammonium fluoride.

5. The method of claim 1 in which the ultimate product consists of X-combretastatin A-4 3'-O-phosphate wherein "X" is selected from the group consisting of cesium, calcium, lithium, magnesium, manganese and zinc.

6. The method of claim 1 in which the ultimate product consists of Y-combretastatin A-4 3'-O phosphate wherein "Y" is selected from the group consisting of imidazole, morpholine, piperazine, piperidine, pyrazole and pyridine.

5

7. The method of claim 1 in which the ultimate product is Z-combretastatin A-4 3'-O phosphate wherein "Z" is selected from the group consisting of adenosine, cinchonine, glucosamine, quinine, quinidine, tetracycline, and verapamil.

10

8. The method of synthesizing a trans-isomer of combretastatin A-4 Pro-drug comprising:

15

dissolving combretastatin A-4 in acetonitrile;

cooling the solution to -25°F;

adding carbon tetrachloride to the cooled solution with stirring;

20

adding 4-dimethylaminopyridine and dibenzyl phosphate to the cooled, stirred solution and warm to room temperature;

extracting the solvent from said room temperature solution to provide 3'-O-Bis(benzyl) phosphoryl- 3, 4, 4', 5 - tetramethoxy-(E)-stilbene;

25

admixing chlorotrimethyl silane with said 3'-O-Bis(benzyl) phosphoryl- 3, 4, 4', 5 - tetramethoxy-(E) stilbene;

30

separating the solvent from the admixed solution with ethyl acetate to form an extract;

dissolving the extract in methanol;


adding sodium methoxide to said dissolved extract to form a second solution; and

5 removing the methanol from the second solution and recrystallizing the solid from said second solution to form a trans-isomer of combretastatin A-4 prodrug.

10 9. Combratstatin A-4 metal and ammonium phosphate prodrugs, and

trans-combratstatin A-4 prodrugs having the structure

15



20

wherein Y is selected from the group consisting of cesium, calcium, lithium, magnesium, manganese, zinc, imidazole, morpholine, piperazine, piperidine, pyrazole, pyridine, adenosine, cinchonine, glucosamine, quinine, quinidine, tetracycline, and verapamil.

AMENDED CLAIMS

[received by the International Bureau on 24 May 1999 (24.05.99);
original claims 1-5 and 8-9 amended; new claim 10 added.
remaining claims unchanged (4 pages)]

1. The method of synthesizing combretastatin A-4 prodrugs as monosodium and disodium phosphate salts and trans-combretastatin A-4 prodrugs comprising:

5

admixing combretastatin A-4 with a phosphorylating agent to form a phosphate ester of combretastatin A-4 having protective groups thereupon;

10

selectively cleaving said phosphate ester protective groups with a cleaving agent to yield a phosphoric acid derivative of combretastatin A-4; and

15

treating said phosphoric acid derivative of combretastatin A-4 with sodium methoxide to yield combretastatin A-4 prodrug disodium phosphate, the combretastatin A-4 prodrug monosodium phosphate or a trans-isomer thereof as the ultimate product.

20

2. The method according to Claim 1 in which said phosphorylating agent is selected from the group consisting of dibenzyl phosphite/carbon tetrachloride, di-tert-butyloxy (N,N-diethylamido) phosphine and bis[2-(trimethylsilyl)ethoxy]N,N-diisopropylamidophosphine.

25

3. The method of Claim 1 in which said cleaving agent is selected from the group consisting of: iodotrimethylsilane, trifluoroacetic acid, and tetrabutylammonium fluoride.

4. The method of Claim 2 in which said cleaving agent is selected from the group consisting of: iodotrimethylsilane, trifluoroacetic acid, and tetrabutylammonium fluoride.

5. The method of claim 1 in which the ultimate product consists of X-combretastatin A-4 3'-O-phosphate wherein "X" is selected from the group consisting of cesium, calcium, lithium, magnesium, manganese, sodium, potassium and zinc.

5

6. The method of claim 1 in which the ultimate product consists of Y-combretastatin A-4 3'-O phosphate wherein "Y" is selected from the group consisting of imidazole, morpholine, piperazine, piperidine, pyrazole and pyridine.

10

7. The method of claim 1 in which the ultimate product is Z-combretastatin A-4 3'-O phosphate wherein "Z" is selected from the group consisting of adenosine, cinchonine, glucosamine, quinine, quinidine, tetracycline, and verapamil.

15

8. The method of synthesizing a trans-isomer of combretastatin A-4 Pro-drug comprising:

dissolving combretastatin A-4 in acetonitrile;

20

cooling the solution to -25°F;

adding carbon tetrachloride to the cooled solution with stirring;

25

adding 4-dimethylaminopyridine and dibenzyl phosphate to the cooled, stirred solution and warm to room temperature;

extracting the solvent from said room temperature solution to provide 3'-O-Bis(benzyl) phosphoryl- 3, 4, 4', 5 - tetramethoxy-(E)-stilbene;

admixing chlorotrimethyl silane with said 3'-O-Bis(benzyl) phosphoryl-3, 4, 4', 5 - tetramethoxy-(E) stilbene;


5 separating the solvent from the admixed solution with ethyl acetate to form an extract;

dissolving the extract in methanol;


10 adding sodium methoxide to said dissolved extract to form a second solution; and

15 removing the methanol from the second solution and recrystallizing the solid from said second solution to form a trans-isomer of combretastatin A-4 prodrug.

9. Combratstatin A-4 metal and ammonium phosphate prodrugs, and trans-combratstatin A-4 prodrugs having the structure



cis



trans

25 wherein X is selected from the group consisting of cesium, calcium, lithium, magnesium, manganese, sodium, potassium, zinc, imidazole, morpholine, piperazine, piperidine, pyrazole, pyridine, adenosine, cinchonine, glucosamine, quinine, quinidine, tetracycline, and verapamil.

10. The method of claim 1 in which the ultimate product is recrystallized.

1/2

a





FIGURE 1

2/2

b



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/00419

A. CLASSIFICATION OF SUBJECT MATTER																				
IPC(6) :C07F 9/09 US CL :558/197, 207, 210, 215 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED																				
Minimum documentation searched (classification system followed by classification symbols) U.S. : 558/197, 207, 210, 215																				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
A - Y	US 5,561,122 A (PETTIT) 01 October 1996 (01/10/96) see entire document, especially columns 1 and 2.	1-8 — 9																		
Y	Database CAPLUS on STN, Chem Abstracts, (Columbus OH, USA) No. 94:197470 , TANIGUCHI, M. et al. 'Study of phosphate esters as prodrugs. Part 3. Synthesis and evaluation in vitro of 4-acetamidophenyl phosphate.' Chem. Pharm. Bull. Abstract, February 1981, 29(2), 577-580.	9																		
Y	US 4,996,237 A (PETTIT et al.) 26 February 1991 (26/02/91) see entire document, especially examples.	9																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T*</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier document published on or after the international filing date</td> <td>*Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*A*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
B earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family																		
O document referring to an oral disclosure, use, exhibition or other means																				
P document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 02 MARCH 1999	Date of mailing of the international search report 24 MAR 1999																			
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized Officer JEAN F VOLLANO Telephone No. (703) 308-1235																			

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/00419

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAS ONLINE, BEILSTEIN, GMELIN, CASREACT

search terms: phosphorylation, structure search, combrestatin, phosphate ester, prodrug, dibenzyl phosphite, diethylamido, phosphine, diisopropylamido phosphine, phenol